Neuros Australia secures additional A$6M for sleep apnoea DBS pivotal trial preparation
Summary
Brisbane-based Neuros Australia raised an A$6M extension from Brandon Capital to fund the regulatory submissions and pre-pivotal feasibility work required before their Dreamforge closed-loop hypoglossal nerve stimulator can enter a pivotal trial. The TGA (Australia) granted the company a breakthrough designation equivalent in November 2024.
Why it matters
TGA Breakthrough designation gives Neuros Australia an accelerated Australian regulatory pathway alongside ongoing international clinical development. Australia's strong MedTech regulatory infrastructure and Brandon Capital's deep industry network make Brisbane an effective base for Asia-Pacific sleep apnoea device development.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial